{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:17:04Z","timestamp":1784128624891,"version":"3.55.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"BeOne Medicines USA, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.1080\/10428194.2025.2541911","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:00:25Z","timestamp":1756767625000},"page":"2238-2248","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma"],"prefix":"10.1080","volume":"66","author":[{"given":"Bijal","family":"Shah","sequence":"first","affiliation":[{"name":"Moffitt Cancer Center","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Challagulla","sequence":"additional","affiliation":[{"name":"BeOne Medicines","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[{"name":"BeOne Medicines","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Ren","sequence":"additional","affiliation":[{"name":"ConnectHEOR Ltd","place":["London, UK"]},{"name":"SCHARR, University of Sheffield","place":["Sheffield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"ConnectHEOR Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Gautam","sequence":"additional","affiliation":[{"name":"ConnectHEOR Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"BeOne Medicines","place":["San Carlos, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, Deming Department of Medicine, Tulane University","place":["New Orleans, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"Alfred Hospital and Monash University","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"e_1_3_5_2_1","article-title":"Mantle cell lymphoma","author":"Lynch DT","year":"2025","unstructured":"Lynch DT, Koya S, Dogga S, et\u00a0al. Mantle cell lymphoma. StatPearls. Treasure Island (FL). 2025;","journal-title":"StatPearls. Treasure Island (FL)"},{"key":"e_1_3_5_3_1","first-page":"326","article-title":"Current treatments in mantle cell lymphoma","volume":"37","author":"Avyakta Kallam M","year":"2023","unstructured":"Avyakta Kallam M, Vose JM. Current treatments in mantle cell lymphoma. Oncology (Williston Park). 2023;37:326\u2013333.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2016.07.012"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104085"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3149"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129677"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.017"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107385"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01755-5"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01353-w"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28052400"},{"key":"e_1_3_5_13_1","volume-title":"Brukinsa\u00ae (zanubrutinib)","author":"BeOne Medicines","year":"2025","unstructured":"BeOne Medicines. Brukinsa\u00ae (zanubrutinib). US FDA Prescribing Information, San Carlos, CA, USA: BeOne Medicines; 2025."},{"key":"e_1_3_5_14_1","volume-title":"Calquence\u00ae (acalabrutinib)","author":"AstraZeneca","year":"2025","unstructured":"AstraZeneca. Calquence\u00ae (acalabrutinib). US FDA Prescribing Information, Wilmington, DE, USA: AstraZeneca; 2025."},{"key":"e_1_3_5_15_1","unstructured":"J&J Pr. Update on Imbruvica\u00ae (ibrutinib) U.S. accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications April 06 ; 2023."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3703"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282469"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004074"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1511"},{"key":"e_1_3_5_23_1","volume-title":"NICE DSU TECHNICAL SUPPORT DOCUMENT 18: METHODS FOR POPULATION-ADJUSTED INDIRECT COMPARISONS IN SUBMISSIONS TO NICE","author":"Phillippo DM","year":"2016","unstructured":"Phillippo DM, Ades AE, Dias S, et\u00a0al. NICE DSU TECHNICAL SUPPORT DOCUMENT 18: METHODS FOR POPULATION-ADJUSTED INDIRECT COMPARISONS IN SUBMISSIONS TO NICE. UK: university of Sheffield; 2016."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1681"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12579"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1565"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1718"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6473"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01174-3"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2268228"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181352"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.09.012"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2020.103496"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01376-1"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.2163"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.162"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17063"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv074"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0036-x"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02822-z"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969432.47546.cf"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2025.2541911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:45Z","timestamp":1764547245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2025.2541911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10,15]]}},"alternative-id":["10.1080\/10428194.2025.2541911"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2025.2541911","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}